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ABSTRACT
Objectives To provide toxicokinetic and clinical evidence
of the hydrolytic effect of paraoxonase-1 (PON1) on
acute organophosphate poisoning in rats.
Methods 40 male Wistar rats were randomised into
four equal groups. Dichlorvos administration group
(A group) underwent dichlorvos injection (dissolved in
corn oil) using intraperitoneal (ip) dose of 10 mg/kg.
PON1 pretreatment group (B group) was injected with
PON1 in the tail vein (intravenous), dose 9600 U/kg, 30
min prior to dichlorvos administration. In the treatment
group (C group), atropine 0.05 mg/kg and pyraloxime
chloride (PAM-CI) 120 mg/kg were injected intravenously
within 2 min after dichlorvos administration. Finally, in
the co-treatment group (D group), PON1 was injected
intravenously with a dose of 9000 U/kg 30 min prior to
dichlorvos administration; atropine 0.05 mg/kg and PAM-
CI 120 mg/kg were injected intravenously within 2 min
after dichlorvos administration. Blood was collected after
administration. Plasma dichlorvos concentration was
detected by liquid chromatography-mass spectra
(LC-MS) method and clinical signs were observed.
Toxicokinetic parameters were calculated in a statistical
moment model.
Results AUC (0/N) in group B was statistically
different from that in groups A and C (p<0.05), while it
was not different from group D (p>0.05); there was no
statistical difference between group A and group C
(p>0.05). The statistical results of Cmax were the same
as those of AUC (0/N). There were no differences of
MRT between four groups (p>0.05). Clinical signs can
be improved by PON1 and atropine + PAM-CI, and
co-treatment can relieve signs more effectively.
Conclusion PON1 can decrease the amount of
dichlorvos that entered the blood, lowered the peak
concentration and relieved clinical signs.
Serumparaoxonase-1(PON1)isanA-esterasethatis
associated with high-density lipoprotein (HDLs).
The products of PON1 gene exist widely in
mammals, with the highest activity in liver and
blood. It is involved in the detoxiﬁcation of organo-
phosphate insecticides, such as chlorpyrifos oxon,
diazoxon,paraoxonanddichlorvos.
1 2Asaresult,itis
considered to have great signiﬁcance in the detoxi-
cation of organophosphate compounds. Therefore,
PON1 may prevent tissue damage from organo-
phosphate toxicity, especially in the central nervous
system.Therehavebeenstudiesdesignedtoevaluate
the protective effect of PON1 to organophosphates
in vitro or by measuring inhibition of acetyl cholin-
esterase in different tissues, but studies on organo-
phosphateconcentrationchangesinvivoarerare.
3e5
In the present study, puriﬁed rabbit serum PON1
was administered to rats intravenously and concen-
tration of dichlorvos in blood was detected at
different time points to analyse the effect of PON1
on toxicokinetics of dichlorvos.
MATERIALS AND METHODS
Material
Dichlorvos (>99.5% pure) was obtained from
Tianjin Agriculture Co., Ltd; acetonitrile, indo-
methacin and methanoic acid (chromatographic
pure) were homemade reagents.
Clean grade male Wistar rats, weighing
250e300 g, were obtained from Beijing Vital River
Experimental Animal Co., Ltd. The animals were
fed ad libitum in the experiment.
ÄKTA puriﬁer automatic chromatography was
manufactured by GE Company (Bridgeport,
Connecticut, USA). TSQ Quantum Ultra, produced
by Thermo Finnigan (San Jose, California, USA).
Eppendorf 5417-R refrigerated centrifuge was
manufactured by Eppendorf Company (Hamburg,
Germany).
Dose schedule and sample collection
40 male Wistar rats were randomised into four
equal groups. The dichlorvos administration group
(A group) underwent dichlorvos injection
(dissolved in corn oil) using intraperitoneal (ip) dose
of 10 mg/kg. The PON1 pretreatment group
(B group) was injected with PON1 in the tail vein
(intravenous), dose 9600 U/kg, 30 min prior to
dichlorvos administration (10 mg/kg ip). In the
treatment group (C group), atropine 0.05 mg/kg
and pyraloxime chloride (PAM-CI) 120 mg/kg were
injected intravenously within 2 min after
dichlorvos administration (10 mg/kg ip). Finally, in
the co-treatment group (D group), PON1 was
injected intravenously in a dose of 9000 U/kg
30 min prior to dichlorvos administration (10 mg/
kg ip); atropine 0.05 mg/kg and PAM-CI 120 mg/kg
were injected intravenous within 2 min after
dichlorvos administration.
Blood of 0.2 ml was collected at 3 min, 5 min,
10 min, 20 min, 30 min, 1 h, 2 h, 4 h and 6 h after
administration from the eye veins. Blood was
centrifuged at 5000 r for 3 min and the supernatant
was collected and stored in  808C for dichlorvos
detection.
Clinical signs after dichlorvos poisoning were
observed. According to Gaidukov,
6 all clinical signs
noted following dichlorvos intoxication were cate-
gorised to mild, moderate or severe reactions. Mild
reactions were characterised by straub tail and/or
ataxia and/or diarrhoea. Moderate reactions
consisted of, in addition, decreased motor activity
and/or dyspnoea, while animals with severe reac-
tions exhibited ventral position and/or tremors as
well. The overall reactions observed following
dichlorvos intoxication were scored using semi-
quantitative gradingofﬁvegrades(0e4),takinginto
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Original articleconsideration the severity of the reactions (0¼no reactions,
1¼mild reactions, 2¼moderate reactions, 3¼severe reactions,
4¼mortality).Becausetherewerenodeathsintheexperiment,no
rats scored 4.
Puriﬁcation of rabbit serum PON1
Paraoxonase was puriﬁed from rabbit serum as previously
described in detail.
7 The collected protein was subjected to
centrifugal ultraﬁltration on centrpuls YM-10 (Millipore, Bill-
erica, Massachusetts, USA) so as to concentrate to >3000 U/ml.
The enzyme was dissolved in buffer solution (136 mM NaCl,
0.1 mM CaCl2) for injection before usage.
LC-MS method
Sample preparation
Plasma aliquot of 50 ml was added to 2.5 ml of the internal
standard indomethacin solutions that was prepared in methanol
of 50 ng/ml. Then, acetonitrile (100 ml) was added to the
mixture. The resulting mixture was vortex-mixed for 1 min and
then centrifuged at 12000 r for 5 min. The supernatant was
ﬁltered through a 0.45-mm Millex
-LH ﬁlter, and 20 ml of the
ﬁltrate was injected into the LC-APCI-MS.
LC-MS condition
The HPLC analysis was performed on a Diamonsil C18 column
(15034.6 mm inside diameter, 5 mm.) equipped with an
phenomenex C18 guard column (433.0 mm inside diameter) at
room temperature. Fluid phase was used with solvent consisting
of acetonitrile water methanoic acid (90:10:0.2, v/v/v) at
a ﬂow rate of 0.45 ml/min. The solutions were ﬁltered through
a 0.45 mm Millex
-LH ﬁlter before use.
A Thermo Finnigan TSQ Quantum Ultra tandem mass
spectrometer equipped with an APCI interface operated in the
positive ion mode. The capillary voltage was set to 4.2 kV. The
capillary temperature was 2708C, and the desolvation temper-
ature was 4208C. Nitrogen was used as desolvation gas (pressure
30 Arb) and assist gas (pressure 5 Arb), and argon was used as
collision gas at a pressure of 1.2 mTorr. Detection was
performed in selected reaction monitoring (SRM) mode. The
collision-induced dissociation voltages were 23 eV (dichlorvos)
and 44 eV (indomethacin), respectively. Ionic reaction for
quantitative analysis was m/z 221 / m/z 109 (dichlorvos) and
m/z 358 / m/z 111 (indomethacin), respectively. Scan time
was 0.3 s.
8
Following analysis by an LC-APCI-MS system, the retention
time for dichlorvos was 4.07 s, and that for indomethacin was
4.92 s (ﬁgure 1).
Linearity
Added dichlorvos standards to blank plasma detected the ratio of
peak area of 6 mg/ml, 5 mg/ml, 2 mg/ml, 1 mg/ml, 0.5 mg/ml and
0.2 mg/ml of dichlorvos to internal standard peak area.
With deﬁned dichlorvos standards peak area as X-axis, ratio of
dichlorvos standards peak area to internal standard peak area as
Y-axis, we got the regression line of dichlorvos: Y¼ 0.0404282
+0.16048*X, R
2¼0.9945.
The linearity was 0.2 6 mg/ml.
Statistics
A statistical moment model was used to calculate toxicokinetics
parameters for dichlorvos by 3p97 software. Statistical analyses
were conducted using SPSS16.0 software.
RESULTS
Toxicokinetics of dichlorvos
Dichlorvos concentration
The concentrations of dichlorvos in B group were statistically
differentfromAgroup(p<0.05),whileatropine+PAM-CIdidnot
alter dichlorvos concentration statistically (p>0.05) (table 1).
Dichlorvos toxicokinetics parameters
The toxicokinetics parameter differences between four groups
were performed by ANOVA. There were no statistical differ-
ences between AUC (0/N) of groups A and C, but the effect of
PON1 was obvious in groups B and D when compared with
group A. There were no statistical differences between MRT
(0/N) of the four groups. Cmax was obtained by observing the
peak concentrations in table 1. The statistical result coincided
with that of AUC (0/N) (table 2).
Clinical signs
The clinical signs were alleviated by PON1, atropine+ PAM-CI
and co-treatment, and the effect of PON1 was not different
with atropine+ PAM-CI statistically. However, co-treatment
achieved the best effect (table 3).
DISCUSSION
The 1/2 LD50 (LD50,1 8 e20 mg/kg by ip) of dichlorvos was
selected so that the most severe signs of poisoning would be
elicited but no death arose through preliminary experiment. The
Figure 1 Blank blood with IS and dichlorvos standard. Dichlorvos was
shown at 4.07 min (upper panel), and IS was shown at 4.92 min (lower
panel).
Table 1 Time-dichlorvos concentration of four groups
Time
(h)
A group
(mg/m)
B group
(mg/ml)
C group
(mg/ml)
D group
(mg/ml)
0.05 1.8460.85 0.7660.17* 1.8360.40 0.7660.07*
0.08 3.3160.31 1.2260.13* 3.1360.27 1.3360.21*
0.17 5.3660.63 2.9160.18* 5.2860.55 2.9060.32*
0.33 2.8560.30 1.5760.26* 2.7460.42 1.5460.05*
0.5 1.9360.26 0.9960.18* 1.8760.34 0.9560.17*
1 1.3560.22 0.6460.08* 1.2560.10 0.6460.10*
2 1.0960.21 0.3560.07* 1.0560.16 0.3560.01*
4 0.6660.16 0.2360.01* 0.6560.09 0.2360.03*
6 0.3760.06 0.2260.01* 0.3560.02 0.2160.01*
All the data were expressed as mean6 SD.
*p<0.01, concentration data were compared with A group by t test. There were statistical
differences between group B and group A and between group C and group A.
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Original articledose is different from the larger dose exposures that occur in
clinical situations and experimentally in vitro; however, it allow
us to evaluate toxicokinetics of dichlorvos.
The results of the study suggested that PON1 can effectively
decrease blood dichlorvos concentration, reduce the peak
concentration of dichlorvos and lessen the amount that enters
the blood. It is possible that a high degree of protection was
provided by PON1 pretreatment in animals challenged with
organophosphates by measuring cholinesterase activities in
different tissues.
10e12 Our results provide further direct evidence
by showing changes in concentration with PON1 pre-treatment.
We also compared the hydrolytic effect of PON1 with atropine
+PAM, the most widely used therapy clinically. The results of
the study show that atropine +PAM does not affect the
metabolism of dichlorvos, which is consistent with the ﬁndings
of a previous study.
13 Co-treatment does not alter the impact of
PON1 on dichlorvos concentrations, which implies that there is
no interaction between PON1 and atropine+ PAM-CI; there-
fore, it is postulated that co-treatment may be feasible in the
clinical treatment of human organophosphate-related toxicity.
We also investigated the clinical signs of the four groups.
Decreased blood dichlorvos concentration in the PON1
pretreatment group resulted in better clinical outcome when
compared with the dichlorvos administration group. At this
dose, the PON1 effect is comparable to that of atropine+ PAM-
CI, which is the most common antidotal treatment used clini-
cally. In addition, another novel ﬁnding in our study was that
the clinical signs were relieved the most by co-treatment. This
may have important implications on the future treatment of
organophosphates poisoning.
Interest in PON1 arises from the hypothesis that individuals
with low serum activity of this enzyme would be expected to
have a diminished ability to metabolise organophosphates. This
hypothesis implies that serum PON1 has a pivotal role in the
detoxiﬁcation of the organophosphate. After the hypothesis was
raised, some studies have been designed to evaluate the protec-
tive effect of PON1 by pretreating animals with PON1 before
organophosphates administration. Such studies are needed
before any deﬁnite inference can be drawn on the role that
serum paraoxonase levels have in the protective effect on
insecticides. However, in the treatment of human organophos-
phate-related toxicity, antidotes are administered after exposure,
so further investigations of PON1 should be conducted with
PON1 administration after organophosphate exposure on the
theoretical basis of protective function.
In conclusion, PON1 can hydrolyse organophosphates in vivo
and improve clinical signs of organophosphate toxicity. The use
of PON1 in organophosphates poisoning requires further
investigations.
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Table 2 Toxicokinetics parameters of dichlorvos
Parameter A group B group C group D group
AUC(0/N)
(mg/ml*h)
11.2461.63 4.2560.41 10.7160.97 4.6760.99
MRT (h) 7.9361.40 8.5062.05 7.6560.87 13.8965.80
Cmax (mg/ml) 5.3660.63 2.9160.18 5.2860.55 2.9060.32
All the data were expressed as mean6 SD.
Table 3 Clinical signs scores of four groups
Group
Score
0123
A group 0 0 5 5
B group 0 2 7 1
C group 0 5 5 0
D group 2 6 2 0
Ridit analysis was used to analyse the differences between the data of clinical signs scores
of four groups,
9 where p<0.05 was regarded as signiﬁcant.
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